Abstract:The ability to define thresholds for the clinical significance (clinical importance) of outcome measures in dementia drug research is critical to determining the changes on outcome measures that patients and families would consider worth the cost and worth risking the side effects of medications (i.e., clinical importance is central to informed consent when starting such medications). Thresholds for clinical significance are also required for drug trial sample size calculation (if the studies are to be powered to detect clinically important difference) and for decisions regarding whether medications should be accepted on formularies and should be funded. To better understand what measures of clinical significance have been employed in dementia drug research, a systematic review was performed of double-blind randomized controlled trials (RCTs) of cholinesterase inhibitors and memantine in subjects with Alzheimer's disease, vascular dementia, mixed dementia, and mild cognitive impairment. Of the 57 dementia drug RCTs reviewed, only 46% discussed the clinical significance of their results. The most commonly cited measures of clinical significance were a 4-point change in the Alzheimer's Disease Assessment Scale--Cognitive Subscale and changes on global scales. The majority of measures of clinical significance were opinion based. Only one study empirically measured patient perspective regarding thresholds for clinical significance. Despite being central to the interpretation of trial results and to decisions regarding whether to employ trial findings in clinical practice, patient- and caregiver-centered measures of clinical significance have not been adequately studied and integrated into dementia drug RCTs. It is recommended that discussions of clinical importance receive greater emphasis in research standards published by organizations such as the CONSORT group (http://www.consort-statement.org). Drug formulary review committees and licensing agencies (e.g., U.S. Food and Drug Administration, European Agency for the Evaluation of Medicinal Products, Health Canada) should consider requiring an assessment of clinical significance of the drugs they review. To move this field forward, funding agencies should consider initiating requests for proposals focused on the determination of the minimally clinically important difference (MCID) of outcome measures employed in dementia research. Once empirical data on MCIDs are available, then these funding agencies should consider supporting a consensus conference to review and select the optimal measures of clinical importance in dementia research. A preliminary organizational framework of measures of clinical significance is presented in this article to facilitate the work of such a consensus forum.

Measurement tools of resource use and quality of life in clinical trials for dementia or cognitive impairment interventions: A systematically conducted narrative review

Measurement tools of resource use and quality of life in clinical trials for dementia or cognitive impairment interventions: protocol for a scoping review

A qualitative exploration of the content and face validity of preference-based measures within the context of dementia

Outcomes measures in a decade of dementia and mild cognitive impairment trials

Tools to assess the quality of life in patients with Parkinson’s disease: a systematic review

How to measure quality of life in shared-housing arrangements? A comparison of dementia-specific instruments

Quality of Life in Mild Cognitive Impairment and Mild Dementia Associated with Alzheimer's Disease: A Systematic Review

Assessments scales for the evaluation of health-related quality of life in Parkinson's disease, progressive supranuclear palsy, and multiple system atrophy: a systematic review

Measuring quality of life in clinical trials: a taxonomy and review.

Cross-sectional study assessing the feasibility of measuring residents′ Quality of Life in English care homes and assessing the construct validity and internal consistency of measures completed by staff-proxy.

Instruments for assessing social health in the context of cognitive decline and dementia: a systematic review

Nonpharmacological Interventions to Improve Depression, Anxiety, and Quality of Life (QoL) in People With Dementia: An Overview of Systematic Reviews

Instruments to evaluate mental well-being in old age: a systematic review

The measurement of disability in the elderly: a systematic review of self-reported questionnaires.

Dementia care mapping as a research tool

The use of the EQ-5D as a measure of health-related quality of life in people with dementia and their carers

Identifying instruments to quantify financial management skills in adults with acquired cognitive impairments

Systematic Review of Measures of Clinical Significance Employed in Randomized Controlled Trials of Drugs for Dementia

A scoping review of the use of visual tools and adapted easy-read approaches in Quality-of-Life instruments for adults

A Comprehensive Approach to Psychometric Assessment of Instruments Used in Dementia Educational Interventions for Health Professionals: a Cross-Sectional Study.

Facilitating clinical use of the Amsterdam Instrumental Activities of Daily Living Questionnaire: Normative data and a diagnostic cutoff value